On the afternoon of December 13, north stock exchange Northland touched the limit. As of press time, it was 26.07 yuan, up 29.96%. The cumulative increase in the past 10 trading days is 75%, and the increase is 147% in the year.
On the news side, the first refinancing project of the listed company on the Beijing Stock Exchange was released. Northland recently announced that it intends to issue no more than 32 million shares to specific targets by auction, accounting for 12.44% of the current total share capital, and it is expected to raise no more than 300 million yuan.
According to the draft increase, Northland's fixed increase financing will be used for three projects: drug research and development projects, biological engineering new drug industrialization projects and supplementary working capital, using the raised funds of 82.17 million yuan, 189.289 million yuan and 28.5410 million yuan respectively. Among them, the total investment in the bioengineering new drug industrialization project was 269.7366 million yuan, and the project had raised 80.4476 million yuan at the time of the initial public offering.
Founded in June 2004, Northland was listed on the New Third Board in February 2009, promoted to the selected layer of the New Third Board in November 2020, and registered on the Beijing Stock Exchange in November this year.
According to public information, Northland is an innovative biopharmaceutical company specializing in the research and development, production and sales of gene therapy drugs, recombinant protein drugs and ophthalmic drugs. At present, the company is developing 13 new bioengineering drugs, corresponding to 15 indications, including 7 gene therapy drugs and 6 recombinant protein drugs; 2 phase III clinical studies, 1 phase II clinical study, and the remaining multiple innovative projects are in the preclinical research stage. Northland's NL003 project is scheduled to submit a new drug application in 2022.
According to the data, in 2019, 2020 and from January to September this year, Northland's net profit attributable to the mother was -37.0003 million yuan, -25.351 million yuan and -37.8646 million yuan, and the research and development expenses were 33.0237 million yuan, 24.1444 million yuan and 30.2126 million yuan, respectively.
![5 billion level blockbuster products specialize in the treatment of diabetic foot! The Beijing Stock Exchange rarely has a high price increase[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)